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Conclusions (1) No relationship was found between the 
studied polymorphisms (14094 ACE gene, rs1800469 gene 
TGFβ1, GNB3 gene rs5443, rs5186 AGTR1 gene) and the 
occurrence of primary vesicoureteral reflux. (2) TT geno-
type polymorphism rs5443 GNB3 gene may be a protec-
tive factor for the improved renal function in patients with 
primary vesicoureteral reflux in patients with genotype CC 
or CT.
Keywords Primary vesicoureteral reflux · Genes 
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Introduction
One of the conditions to preserve the homeostasis of the 
urinary tract is normal outflow of the urine from the kid-
neys to the bladder. It is a process conditioned physiologi-
cally by a specific construction of the distal part of ureter, 
which, together with the ureteral orifice to the bladder, is 
a one-way valve to prevent backflow of urine into the kid-
neys [1–3]. In addition to the anatomy (the importance of 
the length of submucosal ureter), valve performance also 
depends on the contractile function of muscles of the blad-
der triangle and distal parts of the ureter. In the event of 
failure of the valve mechanism, the backflow of urine from 
the bladder into the ureter, and then to the kidney occurs 
[4]. Pathological process of reversing the urine is also 
conducive to further other factors, among others, increase 
in intravesical pressure during voiding which comes from 
neurogenic bladder dysfunction, or the existence of func-
tional or anatomical obstruction in bladder outflow. Clini-
cal experience suggests that vesicoureteral reflux (VUR) 
is one of the most common diseases of the urinary tract 
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in children [5]. But epidemiological data are inconclusive 
neither in the subject VUR diagnosis or evaluation of its 
clinical significance [6–10]. This is due to the fact of physi-
ological remodeling processes of the valve mechanism and 
changes in bladder function, especially during the first year 
of life.
This results in a group of sick children, mainly those 
with a low level of reflux, in a withdrawal of the reflux 
symptoms and “self-healing” [11]. In the 1960s of the 
last century observation of Kollermann and Ludwig, dur-
ing the first 4 years of age, the incidence of asymptomatic 
VUR decreased in the group spontaneously from 60 to 5% 
[8, 12]. This was confirmed by a published in 2000 in the 
Journal of Urology study of the natural history of VUR 
indicating that in 60–85% of children with the diagnosis 
made before 30 days of age for an average duration of 20 
consecutive months, there has been a spontaneous cure of 
VUR, in stages III–V, respectively, in 60, 50 and 28% of 
patients [13]. Therefore, today it is believed that the classi-
cal distinction between primary and secondary VUR is too 
simplistic.
In a situation, where according to the International 
Reflux Study Committee the “gold standard” for diagno-
sis of VUR is still voiding cystourethrogram—invasive 
examination aggravating among others to the exposure 
to ionizing radiation and urinary tract infection—it is not 
possible to perform screening in the general population. 
Thus, the available statistics are mostly the result of anal-
ysis of selected population of children with clinical signs 
or initially suspected for VUR, e.g., on the basis of ultra-
sound of the urinary tract [9]. In the population of children 
diagnosed for urinary tract infections, VUR is observed in 
about 31–59% of the cases [7]. It is estimated that the prob-
lem of vesicoureteral reflux applies to 0.4–2% of the total 
population, and the incidence depends on, among others, 
age, gender and race [2, 8, 14, 15]. Epidemiological data 
also suggest 30–50% higher prevalence of this disease in 
families [10, 16–20].
Backflow of the urine into the kidney may result in the 
occurrence of recurrent urinary tract infections and pro-
gressive damage to the renal parenchyma, which, among 
others, reinforces in the occurrence of hypertension and 
the development of reflux nephropathy [5, 8, 21–27]. All 
of these pathologies can lead to end-stage renal failure and 
the need to implement renal replacement therapy [14, 17, 
28–30].
According to the results of a 10-year follow-up of people 
under 20 years of age with low glomerular filtration pub-
lished in 2004 conducted as part of Project ItalKid, vesi-
coureteral reflux was diagnosed in 25% of patients [31]. 
According to the database of North America (NAPRTCS 
Annual Report) from 2003, reflux nephropathy was the 
fourth cause of end-stage renal failure in children and was 
diagnosed in 5.3% patients after kidney transplantation and 
3.5% of patients on dialysis [14]. The objective quantita-
tive assessment of the problem of progression VUR toward 
end-stage renal disease in Europe is not possible due to the 
lack of such data in reports ERA-EDTA and also due to the 
coexistence of other pathologies of the urinary tract (con-
genital anomalies of the kidney and urinary tract, CAKUT) 
[3]. There is the fact that an increased risk of permanent 
kidney damage, especially at high degrees of vesicoureteral 
reflux, remains undeniable, and the effectiveness of treat-
ment (conservative or invasive) is not satisfactory [27, 28, 
32]. It is sought to factors responsible for the development 
and progression of the disease, which may in the future be 
a new cell in diagnosis and/or treatment [33].
In terms of data on the VUR family occurrence, there are 
high hopes that arouse the results of genetic testing con-
ducted by analysis of candidate genes and more recently—
genome association studies (genome-wide association 
study, GWAS) [34–40]. Research in animal models has 
shown an association between VUR and mutations of vari-
ous genes involved in the process of morphogenesis of the 
urinary tract [1].
Purpose
The aim of this study was to determine the relationship of 
selected four polymorphisms with the presence of the pri-
mary vesicoureteral reflux:
1. polymorphism 14094 (insertion/deletion) of the angi-
otensin-converting enzyme gene (angiotensin-convert-
ing enzyme, ACE)
2. polymorphism rs5186 receptor type 1 angiotensin II 
gene (angiotensin II receptor type 1 gene, AGTR1)
3. polymorphism rs1800469 of transforming growth fac-
tor beta-1 gene (transforming growth factor beta 1, 
TGFβ1)
4. rs5443 polymorphism of the beta subunit of the beta-3 
protein G gene (guanine nucleotide-binding protein 
beta subunit G-3 GNB3).
Materials and methods
The study was planned in the “tested case versus control” 
scheme. The study was approved by the Bioethics Commit-
tee of the Medical University of Silesia in Katowice.
Recruitment for the study group was made through the 
patients of the Department of Surgery of Children’s Mal-
formations and Traumatology in Zabrze and Ambulatory of 
Pediatric Urology of the Clinical Hospital nr 1 in Zabrze 
among children, who are currently, or have been previously 
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diagnosed with primary VUR. The studied group included 
patients with VUR during bladder filling in the voiding cys-
tourethrogram or passive VUR, when the bladder generates 
pressure much lower than during micturition, suggesting a 
failure of valve mechanism. In some cases, the diagnosis 
was expanded by the urodynamic study (UDS) to exclude 
functional disorders of the bladder or functional obstruc-
tion and the urethrocystoscopy to exclude anatomical 
obstruction and confirm the incorrect position and width of 
the ureter orifices.
The exclusion criteria were the finding of secondary 
vesicoureteral reflux in the course of the subjective and 
physical examination, urodynamic study and urethrocys-
toscopy, functional or anatomic obstruction, bladder mal-
functions and diagnosis of chronic constipation. The con-
trol group consisted of children treated in Department of 
Surgery of Children’s Malformations and Traumatology 
in Zabrze for reasons other than the urogenital diseases. 
The informed consent was necessary to participate in the 
study made by the patient over the age of 16 years and/or 
in the case of a minor (under 18 years of age)—his legal 
guardian.
The study protocol provided a one-time 4 ml venous 
blood achievement (in order to perform genetic testing) 
during the child’s stay in the hospital, or his routine visits 
to the ambulatory. Demographic data (age, height, weight) 
and information on the age at the diagnosis and current 
renal function were obtained from medical records of 
patients. For each patient, based on serum creatinine, glo-
merular filtration rate (eGFR) was calculated using, respec-
tively, for those under and over 18 years of age—patterns: 
Schwartz and MDRD (The Modification of Diet in Renal 
Disease Study equation).
The study involved 190 patients. The study group was 
comprised of 90 patients with primary vesicoureteral 
reflux, middle-aged 8.9 ± 4.8 years, including 62% of girls 
and 38% boys. The average age of the disclosure of the 
disease was 4.1 ± 2.1 years, and the current serum creati-
nine level was 0.55 ± 0.18 mg/dl (eGFR 105 ± 17.5 ml/
min/1.73 m2). The number of patients with diagnosed on 
the basis of voiding cystourethrogram classified on the 
basis of reflux grade from I to V was, respectively, 1 (1%) 
12 (13%), 42 (47%), 13 (14.5%) and 22 (24.5%). 15% of 
patients were diagnosed with the coexistence of other dis-
eases of the urogenital system: double pelvicalyceal system 
(7) and ectopic kidneys (3), cryptorchidism (3).
The control group consisted of 100 children aged 
13.5 ± 5.7 years, including 36% of girls and 64% boys.
The isolation of genomic DNA and testing for all of the 
analyzed polymorphisms were carried out in the Labora-
tory of Molecular Biology, Department of Internal Dis-
eases, Diabetology and Nephrology in Zabrze, Medical 
University of Silesia in Katowice.
Each test sample was taken once with 4 ml of venous 
blood to the S-Monovette Sarstedt Company syringe sys-
tem, containing potassium edetate. Until the isolation of 
DNA, blood samples were stored at −200 °C. Genomic 
DNA was isolated from peripheral blood according to the 
own modification procedure, using a DNA isolation kit 
from Epicentre Technologies. The precipitated DNA was 
dissolved in TE buffer, the concentration was assessed in 
samples using a NanoDrop spectrophotometer (Thermo 
Scientific), and working solutions were prepared with a 
constant DNA concentration of 0.1 mg/ml and 0.01 mg/l.
Genotyping of 14094 (insertion/deletion) in intron 16 
of the ACE gene was performed according to published 
in 1992 protocol Rigat’a et al. [41]. Genomic DNA frag-
ment containing the polymorphic site: insertion/deletion 
14094 was grown using PCR (polymerase chain reaction) 
using the primers: F: 5′-ACC ACT CTG GAG CCC TCT 
CTT ATC-3′ and R: 5′-GAT GTG GCC ATC ACA GTC 
TTC AGA-3′. The reaction was done in UNO thermocycler 
(Biometra) with temperature profile and the visualization 
and documentation of the results was performed using a gel 
documentation system (VILBER Lourmat). Length of PCR 
product evaluated in the standard length of 50 bp DNA 
Ladder (Fermentas) was 193 base pairs for the D allele 
(deletion) and 480 base pairs for allele I (insertion).
Genotyping of the remaining three polymorphisms, i.e., 
polymorphism-509 C/T polymorphism TGFβ rs1800469), 
C/T at position 825 GNB3 gene (rs5443) and A/C at posi-
tion 1166 of the gene receptor type-1 angiotensin II receptor 
(rs5186), was performed with the use of fluorescent probes 
and TaqMan sets the TaqMan SNP Genotyping Assay (Life 
Technologies) according to manufacturers instructions.
The results were statistically developed by Statistica 10. 
Quantitative data are presented as mean ± standard devia-
tion. For the purpose of comparison of distributions of gen-
otypes and alleles of studied polymorphisms, test χ2 was 
used. The analysis of relationship between studied poly-
morphisms and the degree of reflux vesicoureteral or renal 
function was made using variance test Anova. Due to the 
small size of the study group, for the purpose of statistical 
analysis, patients were divided into 2 subgroups taking into 
account the clinical course of the disease: a group of VUR 
(1–2)—patients with low reflux vesicoureteral (i.e., Stage 
I or II) and a group of VUR (3–5)—patients with a high 
reflux (i.e., Level III, IV or V).
Results
Polymorphism 14094 insertion/deletion gene ACE
The distribution of genotypes in the study group and 
the control group did not differ significantly and were as 
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follows (respectively, VUR group vs. control group): II 
28.9% versus 20.2%, ID 52.2% versus 55.6, 18.9% versus 
DD 24.2%.
The incidence of allele in VUR group and the control 
group did not differ significantly and amounted to: allele I 
and 55% versus 48%, the D allele 45% versus 52%.
There were no differences in the distribution of frequen-
cies of genotypes in the population in relation to the antici-
pated frequency according to the law Hardy–Weinberg 
equilibrium.
Rs5186 polymorphism of the gene AGTR1
There were no statistically significant differences in the 
distribution of genotypes in the study group and the con-
trol group. Specific genotypes were reported in VUR group 
versus the control group at a frequency of AA versus 61.1% 
52.5%, 31.1% versus AC 38.4% CC 7.8% versus 9.1%.
The incidence of allele in VUR group and the control 
group did not differ significantly and amounted to: allele A 
76.7% versus 71.7% C allele (MAF) 23.3% versus 28.3%.
The frequency distribution of genotypes in the popu-
lation did not differ from anticipated by the law Hardy–
Weinberg equilibrium.
Polymorphism rs1800469 gene TGFβ1
The distribution of genotypes in the study group and the 
control group did not differ significantly and were as fol-
lows (respectively, VUR group vs. control group): CC ver-
sus 50% 48.5, 43.3% versus CT 42.4%, 6.7% versus TT 
9.1%.
The incidence of allele in the study groups did not differ 
significantly in VUR group and the control group: C allele 
71.7% versus 69.7%, T allele (MAF) 28.3% versus 30.3%.
The frequency distribution of genotypes in the popula-
tion studied was consistent with the expected according to 
the Hardy–Weinberg law.
Rs5443 polymorphism of the gene GNB3
In the VUR group and the control group, the following fre-
quency of genotypes was observed CC versus 55.5% 50.5, 
35.5% versus CT 41.4, 9% versus TT 8.1%. There were no 
statistically significant differences in the distribution.
The incidence of allele in VUR group and the control 
group did not differ significantly and amounted to: C allele 
73.3% versus 71.2%, T allele (MAF) 26.7% versus 28.8%.
The frequency distribution of genotypes in the popula-
tion studied was consistent with the expected according to 
the Hardy–Weinberg law.
In the case of any of the investigated four polymor-
phisms (14094 insertion/deletion gene ACE, gene AGTR1 
rs5186, rs1800469 gene TGFβ1 and GNB3 gene rs5443), 
there was no difference in the distribution of genotypes 
between patients with vesicoureteral reflux and the control 
group (Table 1) which indicates the absence of their rela-
tionship with the disease.
In the case of the ACE gene polymorphisms 14094, 
TGFβ1 gene rs1800469 and rs5186 gene AGTR1, there 
were no genotype-dependent differences in glomerular fil-
tration observed. In patients with VUR and the TT geno-
type of the gene polymorphism rs5443 GNB3, the glomer-
ular filtration rate was significantly greater than in patients 
with the CC genotype or CT (Tables 2, 3). Comparing 
Table 1  Frequency 
distribution of studied genotype 










II ID DD AA AC CC CC CT TT CC CT TT
VUR group 29 52 19 61 31 8 55.5 35.5 9 50 43 7
K group 20 56 24 53 38 9 51 41 8 49 42 9
p (VUR vs. K) ns ns ns ns
Table 2  Average glomerular filtration depending on the genotype of 
the polymorphism rs5443 gene GNB3 in the VUR study group





Table 3  Variance analysis of the polymorphism rs5442 of the gene 
GNB3 influence on the average glomerular filtration rate
Genotype p
CC versus CT 0.65139
CC versus TT 0.00676
CT versus TT 0.00429
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subgroups separately by genotype GNB3, no statistically 
significant differences in age of diagnosis of VUR or obser-
vation time were observed.
Discussion
The correct process of developing urinary tract prenatally 
determines the proper structure and function of the urinary 
tract, and all disorders lead to developmental defects [3, 42, 
43].
The results of researches prove that vesicoureteral 
refluxes-defects are a group genetically heterogeneous [18, 
35, 36, 39, 40]. The defect of the gene may result in dif-
ferent disease phenotypes. This is dependent, among oth-
ers, on the stage of morphogenesis in which disturbances 
occurred, as well as environmental factors. Thus, VUR is 
present not only as an isolated defect, but also as a compo-
nent for a plurality of congenital syndromes and variable 
penetration of genes causing the disease often to not reveal 
clinically and is not recognized [39, 40].
Studies conducted in recent decades show that there are 
different models of inheritance in predisposition to VUR: 
autosomal dominant or recessive, sex-linked, or condi-
tioned by multiple genes with variable expression and pen-
etrance of genes. There included the analysis of the rela-
tionship of many candidate genes and population studies 
GWAS [34, 35, 38–40]. Unfortunately, in many cases, the 
results were inconclusive and even contradictory.
The present study examined the relationship between the 
occurrence of VUR and selected polymorphisms of four 
genes involved in the multi-directional homeostasis of uri-
nary tract: two genes encoding components of the renin–
angiotensin system (i.e., converting enzyme and receptor 
type 1 angiotensin II), transforming growth factor beta 1 
gene and transmembrane amplifier of biological signals β3 
subunit protein G.
Polymorphism 14094 insertion/deletion gene and ACE 
gene rs5186 AGTR1
Early embryological studies show the current starting from 
the 5th week of age, expression of the components of the 
renin–angiotensin system (RAS) in human fetuses, indi-
cating their important role in the development of urinary 
tract. The mother and fetus have independent systems RAS. 
Since the second half of pregnancy fetal RAS undergo the 
same factors that stimulates mother’s RAS, and the concen-
tration of renin and angiotensin II is greater in utero than 
after birth. Local RAS system takes, among others, role 
in the regulation of cell division, apoptosis and organo-
genesis [44]. Mutations in genes encoding components 
of the renin–angiotensin system lead to the occurrence of 
developmental disorders of kidney and abnormal regula-
tion of blood volume and blood pressure of the fetus [44]. 
In adults, the RAS is an important pathogenic factor in the 
development and progression of many primary and second-
ary diseases of the urinary tract among others by affecting 
on the regulation of sodium levels and system pressure, 
glomerular hemodynamics, and stimulation of mesangial 
fibrosis [45]. Numerous evidence suggests that the renin–
angiotensin system determines multifaceted homeostasis 
of the body. Interesting reports of Italian researchers con-
nect the polymorphisms of the promoter portion of the gene 
AGTR1 with longevity [46].
For many years, studies of polymorphic variants of RAS 
components in terms of their importance in the pathogen-
esis of many diseases are studied [47, 48].
It has been shown that the DD genotype of the gene pol-
ymorphism 14094 angiotensin-converting enzyme (ACE) 
determines the increased activity of the enzyme, which is 
essential for the pathogenesis of cardiovascular diseases 
and renal failure [48]. There is a relationship between the 
variability and the breed of patients [47–49]. However, 
research on the relationship of variation of polymorphic 
insertion/deletion ACE with the occurrence of the primary 
vesicoureteral reflux or threading kidney disease is incon-
clusive [50–57]. From published in 2014 meta-analysis, 
we know that there are no grounds to conclude about the 
impact of polymorphism for predisposition for VUR, or 
chronic renal failure [45]. This is confirmed by the results 
of own research, which showed no significant connection 
between polymorphic variation (insertion/deletion) of angi-
otensin-converting enzyme gene in patients with primary 
vesicoureteral reflux.
Research on A1166C polymorphism (rs5186) gene 
angiotensin II receptor 1 points to his relationship with an 
increased risk of coronary heart disease, heart failure and 
stroke [58]. Known studies are demonstrating the impor-
tance of this polymorphism in the incidence of metabolic 
disorders as metabolic syndrome and the development of 
hypertension [59, 60].
Angiotensin II vasoconstrictor develops its activity by 
receptor type 1, affecting in this way the vascular resistance 
resulting in an increase in blood pressure [45]. Hyperten-
sion frequently coexists with kidney disease and is recog-
nized as an independent risk factor of their chronic damage. 
In the kidneys of patients with vesicoureteral reflux was 
observed increased expression of type 1 receptor (AT1R) 
and type 2 (AT2R) angiotensin II [61]. In terms of literature 
data demonstrating polymorphism rs5186 AGTR1 connec-
tion with the occurrence of diabetic nephropathy, we under-
took a study to determine whether the above-mentioned 
polymorphism predisposes to the original vesicoureteral 
reflux [62]. The results did not show such a relationship. 
This observation is consistent with the observations of 
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other authors and the results of published in 2014 meta-
analysis Braliou et al. [45, 50, 63].
Polymorphism rs1800469 gene TGFβ1
Transforming growth factor beta (TGFβ1) is a cytokine 
with a wide spectrum of activities in both the physiologi-
cal and number of pathological states. On the one hand, it 
is an important regulator of cell proliferation, growth, dif-
ferentiation and apoptosis of cells during embryogenesis, 
and the other plays an important role in tissue repair, acti-
vating the immune response to various damaging agents, to 
stimulate the production and inhibiting the degradation of 
extracellular matrix proteins and controlling the activity of 
other cytokines involved in remodeling of tissues [64, 65]. 
The overexpression of TGFβ1 is a recognized etiological 
factor in pathological fibrosis of the lungs, liver and kid-
neys. In many pathologies of the urinary system, including 
infections of the urinary tract, but also the states of arousal 
RAAS, there is increased excretion of TGFβ1 [65–67] in 
urine. There are various, but ambiguous reports concerning 
the effect of various polymorphisms TGFβ1 to its transcrip-
tional activity or production of the protein [11].
In terms of the wide range of activities, we can expect 
a multi-pathogenetic effect of TGFβ1 for VUR: both as a 
morphogenetic causative factor and factor escalating pro-
gression toward irreversible damage to the renal paren-
chyma. Literature of the last decade has brought results of 
research indicating a link of TGFβ1 polymorphisms both 
with urinary tract infections, as well as with VUR [11, 38, 
66, 67]. However, the impact of studied polymorphisms 
on the degree of damage to the renal parenchyma remains 
ambiguous [64, 67, 68]. It is suggested that these polymor-
phisms are related to damage to the renal parenchyma, not 
so much in the course of the VUR, but the infection caused 
by it [30].
However, in our study we found no relationship between 
polymorphism rs1800469 (formerly described as the 
T-509C) gene, transforming growth factor beta 1 with the 
occurrence of primary vesicoureteral reflux.
Rs5443 polymorphism of the gene GNB3
Part of the cell membrane is composed of three subunits 
(α, β and γ) G protein (guanine nucleotide-binding protein) 
and has a GTP-ase activity, which catalyzes the hydroly-
sis of GTP to GDP. Their role is to transmembrane transfer 
signals of multiple receptors, including hormones, vaso-
active agents, neurotransmitters, and growth factors into 
intracellular effectors such as adenylate cyclase system, 
the route of inositol triphosphate or diacylglycerol and ion 
channels of potassium and calcium [69–75]. This remark-
ably broad spectrum of activity causes that G proteins are 
a very important element in the proper functioning of many 
systems and maintain homeostasis [76, 77]. In 1994, Alfred 
Gilman and Martin Rodbell received the Nobel Prize for 
their research on the structure and function of G proteins.
Many of the data show the clinical importance of C825T 
polymorphism of the gene G protein β3 subunit. Exchange 
of wild-C allele for allele T (i.e., from cytosine to thymine 
at position 825 of the gene) results in the occurrence of 
an alternative way of making the mRNA, resulting in the 
removal of the protein chain β3 subunit 41 amino acids. 
Established molecule-Gβ3 is responsible for increasing the 
biological activity of G proteins [75, 78].
The first studies indicating the role of the C825T poly-
morphism in the pathophysiology of diseases appeared 
already in the 1990s of last century, when, among oth-
ers, Siffert et al. showed a higher incidence of the T allele 
in patients with hypertension [79]. Further research on this 
topic, conducted in differing race, among others popula-
tions, has brought different, sometimes contradictory results 
[80–85]. Many authors investigated the relationship between 
polymorphisms subunit β3 with metabolic abnormalities in 
terms of carbohydrate and lipid metabolism, obesity, diabe-
tes, hypercholesterolemia and insulin resistance [84, 86–91]. 
There are also known studies that have been linking a gene 
polymorphism rs5443 GNB3 with greater risk of cardiovas-
cular disease and Alzheimer’s predisposition or the develop-
ment and progression of cancer [69, 77, 92–98].
According to available literature data, this is the first 
study analyzing the connection between gene polymor-
phism rs5443 GNB3 and the occurrence of primary vesi-
coureteral reflux.
In our study, we found no statistically significant differ-
ences in the distribution of genotypes between people with 
VUR and the control group, which indicates the absence 
of a causal link between the mutation of the allele C and 
the disease. However, it is worth to emphasize that patients 
with VUR and a homozygous genotype TT of gene poly-
morphism rs5443 GNB3 have demonstrated significantly 
greater glomerular filtration rate that the carriers of the C 
allele so patients with the CC genotype or CT. The interpre-
tation of this finding is ambiguous. Her explanation may be 
found in the impact of polymorphism GNB3 to modifica-
tion of glomerular hemodynamics, or the course of intersti-
tial inflammation.
In terms of study by Zeltner et al. [99], it can be concluded 
that the higher glomerular filtration rate means not improved 
functions and exponent of more normal nephrons, but is 
the result of hyperfiltration. In this study, an increased renal 
blood flow (renal plasma flow) and decreased vascular resist-
ance in not suffering from hypertension carriers of the mutant 
allele T were shown. Hyperfiltration can be caused by disor-
ders of renal autoregulation causing as a consequence, trans-
ferring of high system pressure on the renal glomerulus [100, 
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101]. Numerous studies indicate the pathogenic importance 
of carriers of the mutated T allele polymorphism rs5443 in 
terms of susceptibility to hypertension, having the character 
of low-renin hypertension [81, 102]. Among the hypotheti-
cal mechanisms of its development is taken into account inter 
alia increased activity of sodium-hydrogen exchanger NHE-
1, the function of which 30–50% is mediated by G proteins 
and increased reactivity of vascular smooth muscle to vaso-
constrictive factors, such as acting through G protein, norepi-
nephrine and angiotensin II [81, 103]. Observation of patients 
after kidney transplantation has brought an interesting sug-
gestion that the higher blood pressure seen in those with the 
TT genotype polymorphism C825T may be responsible for 
the deterioration of renal function [104]. In fact, epidemio-
logical studies have shown coexistence of hypertension in 
approximately 10% of children and 38–50% of adults with 
vesicoureteral reflux-complicated with renal damage [105]. 
In the case of own research, we do not have, unfortunately, 
data on the prevalence of hypertension in patients with VUR, 
which constitutes a restriction of work and indicates a new 
direction for further research.
Hyperfiltration is per se considered as a risk factor 
for the development and progression of renal damage 
[106–109]. However, there are observations, in which no 
apparent connection between polymorphism of GNB3 and 
reduction in GFR, or the occurrence of end-stage renal 
failure, is found. Studies in patients with biopsy-proven 
IgA nephropathy showed no effect of carriers of the T 
allele on the progression of kidney damage, like those con-
ducted among kidney transplant recipients [104, 110]. True 
Blüthner et al. in a group of dialysis patients with type 2 
diabetes observed frequent carriers of the T allele [111]; 
however, published by Gumprecht et al. [112], analysis 
of the transfer of the T allele in families whose descend-
ant was treated with renal replacement therapy by dialysis 
has not proven relationship of polymorphism rs5443 with 
the occurrence of end-stage renal failure. For a reliable 
analysis of the hyperfiltration in the group of patients with 
primary VUR the future studies should include the exact 
parameters of the kidney filtration and GFR estimated for 
example by cystatin C levels.
The analysis of literature indicates the second direction of 
the interpretation of the own results. Well, it can be assumed 
that the homozygous TT genotype polymorphism rs5443 is a 
protective factor to achieve a better renal function in patients 
with VUR. This concept is supported by numerous reports 
indicating a modifying influence of polymorphism GNB3 on 
the immune system and inflammation process.
Kidney damage in the course of inflammatory conditions 
of the urinary system is the result of the virulence of the 
microorganisms and the reactivity of the immune system 
and the course of the inflammatory response [113–115]. 
The boundary between a protective, i.e., directed at a cure, 
and destructive inflammatory response leading to damage 
to the kidneys is subtle, and it determines, among others, 
reactivity of the immune system to invasion of pathogenic 
factor [114, 116].
Experimental studies in animal models have shown that 
the barrier epithelium of the urinary tract is controlled by 
chemokines, including primarily by interleukin-8 (IL-8), 
and the main effector cells of local defense are neutrophils. 
Individuals prone to acute interstitial nephritis reveal low 
CXCR1 chemokine receptor expression [117]. Studies in 
mice lacking the receptor for IL-8 revealed abnormalities 
of migration of neutrophils and their accumulation at the 
epithelium of the urinary tract, resulting in greater dam-
age to the kidney in the course of their interstitial nephritis 
[118]. Lundsted et al. demonstrated the reduced expression 
of the receptor for IL-8 in children prone to urinary tract 
infections.
Histological studies made in rats with acute interstitial 
nephritis against the infection due to Escherichia coli or 
Pseudomonas aeruginosa indicate dominance renal intersti-
tial mononuclear cells, mainly of the large T cell morphol-
ogy and phenotype “helper/inducer.” This points to the role 
of T cells in the body’s response to invasion of bacteria in 
the renal parenchyma [119].
Lindemman et al. have shown that carriage of allele T 
polymorphism rs5443 modulates cellular response and 
enhances the transformation of lymphocytes after stimu-
lation with antigens. Fraction of CD4+ T cells plays an 
essential role in antigen presentation, i.e., step necessary to 
trigger specific immune response [120].
Interleukin-8 develops its effect through the receptor 
CXC communicating with sensitive to the pertussis toxin 
(PTX) G protein. In their studies, Virchow et al. showed 
that carriers of the allele T had enhanced chemotaxis of 
neutrophils as a result of stimulation of IL-8 and a strong 
chemoattractant formyl-methionyl-leucyl-phenylalanine 
(fMLP)—a protein released during bacterial or mitochon-
drial decay originating from the damaged tissue [110]. The 
effects of the fMLP are mediated by G protein. Block of 
G proteins by pertussis toxin disables the effect of fMLP 
cells [121, 122]. Jahnukainen et al. [114] hypothesized that 
children with increased response to IL-8 have a pronounced 
symptoms of infection, leading to early diagnosis, early 
treatment and the same—to lower renal toxicity. Based on 
the above data, we consider it more likely that the homozy-
gous genotype TT is a protective factor for longer mainte-
nance of normal renal function in patients with VUR.
Conclusions
1. No association was found between the studied poly-
morphisms (14094 ACE gene, the gene AGTR1 
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rs5186, rs1800469 gene TGFβ1, rs5443 gene GNB3) 
and the occurrence of the primary reflux vesicoureteral
2. TT genotype homozygous polymorphism rs5443 
GNB3 gene may be a protective factor to achieve a 
better renal function in patients with primary bladder-
ureteral reflux.
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